Crohn disease (CD) usually evolves by surges interspersed by periods of unpredictable remission. the probability of recurrence of CD in a patient in remission is even stronger if it pre-exists endoscopic lesions of the intestinal mucosa. The mucosal healing exploration needs the realization of an ileo-colonoscopy under general anesthesia which is an invasive procedure, restrictive and expensive, thus prohibiting its too frequent repetition. we do not currently have noninvasive and reliable markers able to predict the occurrence of thrust of CD and allow the introduction of a more suitable treatment. Indeed, relapse prevention is the best way to avoid complications and formation of lesions that lead to the irreversible medical treatment failure and surgery. Since during the CD, it is the immunological changes that lead to inflammation and lesions, we make the assumption that the ability of certain markers immunological to predict a relapse of CD is higher than that of other in particular inflammatory markers. This work should help to identify the profile of patients with CD in remission but at high risk of recurrence. It will specify i) the potential new markers immunological, from the pre-clinical research, predict the onset of a recurrence of CD ; ii) the predictive interest of different inflammatory markers used in routine or during the CD evaluation ; iii) Finally, the stress and the management of stressful events in the occurrence of a relapse. This work also will specify the evolution of different markers at the moment of thrust
Study Type
OBSERVATIONAL
Enrollment
144
Blood, urine and faecal sampling every 3 months
patients fill several questionnaires every month to assess stress and adaptation parameters
CHU Hôpital Hôtel Dieu - Service d'Hépato-Gastroentérologie
Clermont-Ferrand, France
Hospices Civils de Lyon - Groupement Hospitalier Sud - Service d'Hépato-Gastroentérologie
Pierre-Bénite, France
CHU Hôpital Nord - Service d'Hépato-Gastroentérologie
Saint-Etienne, France
Correlation between new immunological markers rate and Crohn's Disease relapse
This outcome will help us to show that regular monitoring of new immunological markers (serum markers of cytotoxicity of lymphocytes, pro- and anti-inflammatory cytokines and urinary and fecal neopterin) let us predict relapse of the disease
Time frame: within 15 months
Correlation between usual immunological markers rate and Crohn's Disease relapse
This outcome will help us to test the ability of inflammatory markers which are already routinely used for diagnostic purposes to predict relapse of CD. These "usual" markers are : fecal calprotectin and lactoferrin, serum ultrasensitive C-Reactive Protein (CRP) and erythrocyte sedimentation rate (ESR)) is being evaluated (serum S100A12 protein, fecal, alpha-1-glycoprotein (orosomucoid) alpha-2 globulin)
Time frame: within 15 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.